Appelbaum F R, Fisher L D, Thomas E D
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Blood. 1988 Jul;72(1):179-84.
We previously published the results of a prospective comparison of continued chemotherapy or marrow transplantation for adults with acute nonlymphocytic leukemia (ANL) who had achieved a first remission. This report updates that study now that greater than 5 years have passed since the last patient was entered. Among 86 patients eligible for comparison, 43 had no donors and were treated with continued chemotherapy, 43 had donors, but 10 declined transplantation and 33 were transplanted. Five-year disease-free survivals are 21% for the chemotherapy group, 48% for the transplant group, and 10% for the group with matched siblings who declined transplantation.
我们之前发表了一项前瞻性比较的结果,该比较针对首次缓解的成年急性非淋巴细胞白血病(ANL)患者进行持续化疗或骨髓移植。本报告对该研究进行更新,因为自最后一名患者入组以来已过去5年多时间。在86名符合比较条件的患者中,43名没有供者,接受持续化疗;43名有供者,但10名拒绝移植,33名接受了移植。化疗组的5年无病生存率为21%,移植组为48%,有匹配同胞但拒绝移植的组为10%。